Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taltz in Idiopathic Subglottic Stenosis
NCT05309616Phase 2Completed
- Sponsor
- Yale University
- Start
- Feb 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ixekizumab in idiopathic subglottic stenosis (ISS), sponsored by Yale University. Started Feb 2025; status: completed.
02
Drugs
ixekizumab
03
Conditions
idiopathic subglottic stenosis (ISS)
Beyond the preview
Go deeper on NCT05309616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309616.